Analysis of individual variation in tirzepatide type 2 diabetes response identifies patient characteristics predicting who achieves the best glycemic and weight outcomes.
Key findingAnalysis of individual variation in tirzepatide type 2 diabetes response identifies patient characte
What the researchers found
Analysis of individual variation in tirzepatide type 2 diabetes response identifies patient characteristics predicting who achieves the best glycemic and weight outcomes.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
7 phase 3 randomized clinical trials pooled using individual participant data. Published in the Journal of the American College of Cardiology.
How the study worked
In publication.
Who was studied
Individual participants from 7 phase 3 tirzepatide RCTs across diverse subpopulations
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.
Journal of the American College of Cardiology, 85(19), 1858-1872
Citation
Aminorroaya, Arya; Oikonomou, Evangelos K; Biswas, Dhruva; Jastreboff, Ania M; Khera, Rohan. (2025). Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.. Journal of the American College of Cardiology, 85(19), 1858-1872. https://doi.org/10.1016/j.jacc.2025.03.516